Pfizer Inc. has decided to stop the development of its obesity pill, danuglipron, after safety concerns emerged from a clinical trial. This move comes as competition heats up with Novo Nordisk and Eli Lilly's successful weight-loss treatments.
Eli Lilly is set to unveil results from trials of orforglipron, its groundbreaking once-daily obesity pill, potentially revolutionizing weight loss treatment by offering a needle-free alternative. Analysts predict it could capture a significant share of the $150 billion GLP-1 market.
Discover how women like Elizabeth Lilly and others are transforming family offices, taking on key investment roles, and showcasing a more conservative approach to wealth management.
Eli Lilly to invest $27 billion in building new US manufacturing plants amid challenges from drug import duties. The move aligns with Trump's push for American manufacturing revitalization.
Discover how Eli Lilly's $50 billion investment in US manufacturing will create high-wage jobs, advance pharmaceutical innovation, and boost economic growth.
Eli Lilly introduces discounted higher doses of the weight loss drug Zepbound in a move to make the treatment more accessible to uninsured patients and address the growing demand for obesity treatments.
Discover how a new study suggests that Ozempic, a drug commonly used for diabetes and weight loss, may also help reduce alcohol consumption and cravings in individuals with alcohol-use disorder.
